High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection
High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection
The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.
Eligibility Criteria:
Histologically documented malignancy
Metastatic or locally unresectable malignancy
Patient may be responding to therapy
Aged 18 to 55 Physiologic years
-- Performance status: PS 0-1
Prior Treatment
Informed Consent
Required initial laboratory data:
White Cell Count Life ≥ 3000/ul
Platelet Count ≥ 100,000/ul
Creatinine ≤ 1.5 x normal
Bilirubin ≤ 1.5 x normal
No current metastases
Creatinine Clearance ≥ 60 cc/min
SGOT < 2.5 x normal
No other serious medical or psychiatric illness which would prevent informed consent or general anesthesia